Anticoagulación en pacientes con fibrilación auricular. ¿Qué dicen las recomendaciones de las guías de práctica clínica?
- José R. González-Juanatey
- Belén Álvarez Álvarez
ISSN: 1409-4142
Year of publication: 2017
Volume: 19
Issue: 0
Pages: 5-8
Type: Article
More publications in: Revista Costarricense de Cardiología
Abstract
Abstract Anticoagulation in patients with atrial fibrillation. What do clinical practice recommendations guidelines say? Atrial fibrillation is one of the most prevalent heart disease. In order to choose the ideal therapy, the risk of hemorrhagic risk should be evaluated with the HASBLED score and the risk of suffering a cerebrovascular event with the CHADSVASC score. It is recommended to use the algorithm of ESC 2016 guidelines for the prevention of stroke in atrial fibrillation, where NOAC should be preferred to vitamin K antagonists.
Bibliographic References
- Gómez-Doblas, JJ.. (2014). Prevalencia de fibrilación auricular en España. Resultados del estudio OFRECE. Rev Esp Cardiol. 67. 259
- Da., Lane,Lip, GY. (2012). Use of the CHA(2)DS(2)-VASc and HAS-BLED scores to aid decision making for thromboprophylaxis in nonvalvular atrial fibrillation. Circulation. 126. 860
- Kirchhof, P.. (2016). ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS: The Task Force for the management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Stroke Organisation (ESO). Eur Heart J. 18. 1609